CMND Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

2.510

Open

2.510

VWAP

2.00

Vol

73.00K

Mkt Cap

3.00M

Low

2.120

Amount

167.00K

EV/EBITDA(TTM)

--

Total Shares

2.00M

EV

-27.00K

EV/OCF(TTM)

--

P/S(TTM)

--

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.

Show More

Events Timeline

(ET)

2026-01-14

09:10:00

Clearmind Medicine Completes Treatment for Second Cohort of CMND-100

2025-12-24 (ET)

2025-12-24

09:20:00

Clearmind Achieves Key Milestones in 2025 FDA-Approved Clinical Trials

2025-12-18 (ET)

2025-12-18

10:40:00

Clearmind Completes Second Cohort Enrollment for CMND-100 Trial

2025-12-16 (ET)

2025-12-16

08:50:00

Clearmind Medicine Completes Patient Enrollment for CMND-100 Second Cohort

2025-12-12 (ET)

2025-12-12

20:00:00

Clearmind Medicine Inc Trading Halted, News Pending

2025-12-12

08:50:00

Clearmind Medicine Publishes Review Article on MEAI for Alcohol Use Disorder

2025-12-12

06:40:00

Clearmind Medicine Regains Nasdaq Compliance

News

an image of Globenewswire

2025-12-31Globenewswire

Clearmind Regains Nasdaq Compliance with Share Price Above $1

an image of Newsfilter

2025-12-31Newsfilter

Clearmind Regains Nasdaq Compliance with Share Price Above $1

an image of Globenewswire

2025-12-24Globenewswire

Clearmind Medicine Advances CMND-100 Clinical Trials for Alcohol Use Disorder

an image of Newsfilter

2025-12-16Newsfilter

Clearmind Completes Patient Enrollment for Second Cohort of CMND-100 Trial

an image of Newsfilter

2025-12-12Newsfilter

Clearmind Publishes Review on MEAI's Potential in Alcohol Use Disorder Treatment

an image of Newsfilter

2025-12-12Newsfilter

Clearmind Regains Nasdaq Compliance with $2.5M Stockholders' Equity

Valuation Metrics

The current forward P/E ratio for Clearmind Medicine Inc (CMND.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Clearmind Medicine Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

0.00

Current PE

0.00

Overvalued PE

0.00

Undervalued PE

0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Find stocks with low float

Intellectia · 2888 candidates

Region: USShares Outstanding: <= 150,000,000

Ticker

Name

Market Cap$

Aditxt Inc

3.00M

Greenwave Technology Solutions Inc

4.00M

Golden Heaven Group Holdings Ltd

5.00M

American Rebel Holdings Inc

3.00M

iPower Inc

6.00M

UTime Ltd

1.00M

Whales Holding CMND

Trading Trends

People Also Watch

Frequently Asked Questions

What is Clearmind Medicine Inc (CMND) stock price today?

The current price of CMND is 2.19 USD — it has decreased -13.1 % in the last trading day.

What is Clearmind Medicine Inc (CMND)'s business?

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.

What is the price predicton of CMND Stock?

Wall Street analysts forecast CMND stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMND is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Clearmind Medicine Inc (CMND)'s revenue for the last quarter?

Clearmind Medicine Inc revenue for the last quarter amounts to -1.00M USD, decreased -7.23 % YoY.

What is Clearmind Medicine Inc (CMND)'s earnings per share (EPS) for the last quarter?

Clearmind Medicine Inc. EPS for the last quarter amounts to -1285827.00 USD, increased 19.37 % YoY.

How many employees does Clearmind Medicine Inc (CMND). have?

Clearmind Medicine Inc (CMND) has 4 emplpoyees as of January 30 2026.

What is Clearmind Medicine Inc (CMND) market cap?

Today CMND has the market capitalization of 3.00M USD.